Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farhad Mahmoudi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progression-related outcomes of teriflunomide in multiple sclerosis clinical trials

    by Farhad Mahmoudi, Nicole Baldwin, Ramon Flores Gonzalez, Solomon Nittala, Kottil Rammohan, Micheline McCarthy, Flavia Nelson

    Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that leads to neurological disability, more pronounced in the progressive phase. Teriflunomide, an oral disease-modifying therapy, has shown potential neuroprotective effects beyond relapse reduction, including preservation of brain integrity and mitigation of disability progression. This review provides supportive evidence of the effects of teriflunomide on disability progression, cognition, and MRI markers of neurodegeneration in MS. Methods: PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched to identify relevant studies evaluating the effects of teriflunomide on disability progression, cognition, and MRI markers of neurodegeneration in MS such as brain volume loss. Clinical trials, extension studies, comparator studies, and real-world observational cohorts were reviewed. Discussion: Teriflunomide demonstrated consistent effects stabilizing disability progression, maintaining cognitive performance, reducing brain volume loss and preserving gray and white matter integrity across multiple studies. Findings from various studies support its role in limiting disability progression. Proposed mechanisms include preservation of mitochondrial integrity, reduction of oxidative stress, and promotion of remyelination. Although higher-efficacy therapies may provide superior inflammatory control, teriflunomide may have an important role in the long-term management of MS. Conclusion: Teriflunomide is emerging as a valuable, multi-faceted contributor to the MS treatment landscape, with data supporting its role in preserving brain volume, slowing disability progression, and maintaining cognitive function. Additionally, its favorable long-term tolerability and minimal immunocompromise effects further support its value as a therapeutic option over the longer course in PwMS.

  • Area postrema syndrome and longitudinally extensive transverse myelitis masquerading as leptomeningeal carcinomatosis

    by Solomon Nittala, Ramon Flores Gonzalez, Farhad Mahmoudi, Flavia Nelson

    Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune demyelinating disease of the central nervous system commonly associated with aquaporin-4 (AQP4) antibodies. Area postrema syndrome (APS), characterized by intractable nausea, vomiting, and hiccups, is a core clinical feature but is frequently misdiagnosed as a gastrointestinal disorder, leading to delays in diagnosis and treatment. A 63-year-old woman with a history of treated breast cancer presented with one week of intractable nausea, vomiting, progressive left lower extremity weakness, and sensory changes. Initial evaluation was unrevealing. MRI demonstrated longitudinally extensive transverse myelitis and an enhancing dorsal medullary lesion consistent with APS, along with diffuse leptomeningeal enhancement raising concern for neoplastic or inflammatory etiologies. Cerebrospinal fluid analysis showed lymphocytic pleocytosis and elevated protein. The patient developed respiratory failure requiring intensive care support. Empiric treatment with high-dose intravenous methylprednisolone and plasma exchange was initiated. AQP4-IgG serology returned positive, confirming NMOSD. Following treatment, nausea and mental status improved, with partial neurological recovery, although significant residual left leg weakness and neurogenic bladder persisted. The patient was discharged to rehabilitation with plans for long-term immunosuppressive therapy. This case highlights APS as an important early manifestation of NMOSD that may mimic gastrointestinal or neoplastic conditions, particularly in patients with complex medical histories. Early recognition of APS and prompt immunotherapy are critical to prevent severe neurological disability and improve outcomes.

  • Open Access

    Choroid plexus volume in Alzheimer's disease: A systematic review and meta-analysis

    by Farhad Mahmoudi, Mohammad Yazdan Panah, Danial Dehghani Firouzabadi, Saeed Vaheb, Hamed Ghoshouni, Ramon Flores Gonzalez, Vahid Shaygannejad, Omid Mirmosayyeb

    Background: Alzheimer's disease (AD) is marked by amyloid-β and tau accumulation, processes increasingly linked to impaired protein clearance and neuroinflammation. The choroid plexus (CP), which regulates cerebrospinal fluid (CSF) production and immune signaling, may contribute to these mechanisms. This review aimed to evaluate alterations in CP volume (CPV) in AD and their clinical significance. Methods: PubMed, Embase, Scopus, and Web of Science were searched up to March 2025. Eligible MRI-based studies comparing CPV between AD patients and healthy controls (HCs), as well as investigations examining associations of CPV with demographic, cognitive, structural, and pathological variables, were included. Random-effects models estimated pooled effect sizes, while narrative synthesis explored associations with clinical and pathological features. Results: Sixteen studies (2004 AD; 883 HCs) met inclusion criteria. Pooled findings demonstrated significantly larger CPV in AD relative to HCs (SMD = 1.05, 95% CI: 0.67 to 1.43; p < 0.01). Narrative review indicated consistent links between CP enlargement and worse cognition, hippocampal and cortical atrophy, ventricular expansion, and increased amyloid and tau deposition. CP changes were also associated with impaired glymphatic clearance and systemic inflammation. Notably, enlargement was observed in mild cognitive impairment, suggesting early involvement in the disease course. Conclusions: CP enlargement may represent a neuroimaging feature of AD, reflecting the interplay between impaired clearance mechanisms and neuroinflammatory processes. Given its visibility on routine MRI, CPV may hold considerable potential as an imaging marker for disease stratification and longitudinal monitoring of AD.


  • Open Access

    Slowly Expanding Lesions in Multiple Sclerosis: A Systematic Review and Meta-Analysis

    by Mohammad Yazdan Panah, Mehra Fekri, Zahra Zahedi, Hossein Bagheri, Saeed Vaheb, Farhad Mahmoudi, Vahid Shaygannejad, Omid Mirmosayyeb

    Background: Slowly expanding lesions (SELs) have been introduced as a radiological marker of chronic active demyelination and smoldering inflammation. These lesions are recognized as indicators of disability worsening and brain atrophy in people with multiple sclerosis (PwMS). We aimed to provide an overview of the available evidence on the prevalence and clinical relevance of SELs in PwMS. Methods: PubMed, Embase, Scopus, and Web of Science were systematically searched up to 25 May 2025, to identify studies evaluating SELs in PwMS. Risk of bias was assessed using the Newcastle–Ottawa Scale. We conducted a thorough review to evaluate the clinical relevance of SELs in MS. Additionally, a meta-analysis was performed using R software to estimate the pooled prevalence of SELs in MS. Results: Twenty studies on 4970 PwMS met the inclusion criteria. Meta-analysis indicated that the pooled prevalence of SELs in PwMS was 57.1% (95% CI: 44.9% to 69.3%). Moreover, the systematic review showed that SELs were associated with chronic neuroinflammation, ongoing demyelination, disability, microstructural damage, and axonal degeneration. Intervention studies also indicated that the number and volume of SELs were decreased following the administration of disease-modifying therapies. Conclusions: SELs are revealed to affect around half of PwMS and are associated with disability and disease progression in MS. These results highlight the potential role of SELs as a critical radiomarker in MS. However, future studies are warranted to validate these preliminary findings.


  • Glymphatic system dysfunction in multiple sclerosis: A systematic review and meta-analysis

    by Farhad Mahmoudi, Omid Mirmosayyeb, Mohammad Yazdan Panah, Saeed Vaheb, Vahid Shaygannejad, Teddy Salan, Flavia Nelson


  • Open Access

    Exploring “Intoxicated Syndrome”: A rare case of cervical kyphoscoliosis due to drug abuse

    by Majid Rezvani, Seyedali Modarres Sadeghi, Farid Masaeli, Anish Thapa, Ashani Shah, Farhad Mahmoudi

    Key Clinical Message: Dropped head syndrome (DHS), marked by severe cervical muscle weakness, causes progressive kyphosis and difficulty in maintaining head posture. This case study reports on a 23‐year‐old male with DHS linked to drug abuse, underscoring the need to consider substance abuse as a cause and highlighting effective surgical treatment.

  • Open Access

    Functional MRI and cognition in multiple sclerosis—Where are we now?

    by Farhad Mahmoudi, Micheline McCarthy, Flavia Nelson

    Multiple sclerosis‐related cognitive impairment (MSrCI) affects most patients with multiple sclerosis (MS), significantly contributing to disability and socioeconomic challenges. MSrCI manifests across all disease stages, mainly impacting working memory, information processing, and attention. To date, the underlying mechanisms of MSrCI remain unclear, with its pathogenesis considered multifactorial. While conventional MRI findings correlate with MSrCI, there is no consensus on reliable imaging metrics to detect or diagnose cognitive impairment (CI). Functional MRI (fMRI) has provided unique insights into the brain's neuroplasticity mechanisms, revealing evidence of compensatory mechanisms in response to tissue damage, both beneficial and maladaptive. This review summarizes the current literature on the application of resting‐state fMRI (rs‐fMRI) and task‐based fMRI (tb‐fMRI) in understanding neuroplasticity and its relationship with cognitive changes in people with MS (pwMS). Searches of databases, including PubMed/Medline, Embase, Scopus, and the Web of Science, were conducted for the most recent fMRI cognitive studies in pwMS. Key findings ifrom rs‐fMRI studies reveal disruptions in brain connectivity and hub integration, leading to CI due to decreased network efficiency. tb‐fMRI studies highlight abnormal brain activation patterns in pwMS, with evidence of increased fMRI activity in earlier disease stages as a beneficial compensatory response, followed by reduced activation correlating with increased lesion burden and cognitive decline as the disease progresses. This suggests a gradual exhaustion of compensatory mechanisms over time. These findings support fMRI not only as a diagnostic tool for MSrCI but also as a potential imaging biomarker to improve our understanding of disease progression.


  • Open Access

    COVID‐19 vaccination in patients with multiple sclerosis: what you need to know – a review

    by Farhad Mahmoudi, Omid Mirmosayyeb, Elnaz Shaabani, Elham Moases Ghaffary, Flavia Nelson

    Background: The appearance of severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) initiated the COVID‐19 pandemic, resulting in millions of confirmed cases and numerous fatalities. In response, rapid vaccine development efforts were launched to mitigate the pandemic's impact. Despite the high efficacy of COVID‐19 vaccines, they are also associated with several common side effects/complications, some of them specific to the multiple sclerosis population. Our goal is to review various types of COVID‐19 vaccines, assessing their efficacy, adverse events, their association with an MS relapse following vaccination, and the influence of disease modifying therapies (DMTs) on vaccines’ efficacy.Methods: The review was based on a database search that included PubMed/Medline, Embase, Scopus, and the Web of Science conducted from January 2020 to July 2024 using the following MeSH terms: MS, COVID‐19, COVID‐19 vaccination, vaccine side effects, and vaccine hesitancy.Results: Receiving any type of COVID‐19 vaccine is a safer and more reliable approach to building immunity compared to becoming infected with the virus. Complications tend to be mild to moderate, occasionally severe. DMTs could affect the humoral response to the COVID‐19 vaccine. Among all DMTs, a notable reduction in the humoral response has been observed in patients who received anti‐CD20 and sphingosine‐1‐phosphate (S1P) receptor modulator drugs after their COVID‐19 vaccination.Conclusion: Despite certain drawbacks, the benefits of the COVID‐19 vaccine significantly outweigh the associated risks, making it a recommended course of action for people with multiple sclerosis (pwMS). However, physicians need to be mindful of potential complications especially in patients undergoing anti CD20 and manage them appropriately.


  • Open Access

    Exploring ‘’Intoxicated Syndrome”: A Rare Case of Cervical Kyphoscoliosis Due to Drug Abuse

    by Majid Rezvani, Seyedali Modarres Sadeghi, Farid Masaeli, Anish Thapa, Ashani Shah, Farhad Mahmoudi

    IntroductionThe cervical spine is a crucial anatomical structure protecting neurologic elements and is fundamental in preserving horizontal gaze. Maintaining normal alignment of the cervical spine, especially in the sagittal plane, is essential for proper physiological functioning and minimizing muscle energy expenditure.(1)Cervical kyphosis is the most prevalent deformity impacting the cervical spine, disrupting its physiology and resulting in considerable disability for the affected individual. This deformity may manifest as either regional or global, and multiple studies have shown its correlation with a diminished quality of life.(2)Dropped Head Syndrome (DHS), also known as floppy head syndrome, is a rare medical disorder characterized by weakness in the neck extensor muscles against gravity. Consequently, a passively correctable chin-on-chest deformity develops.(3)DHS is most commonly associated with various neuromuscular conditions, including mitochondrial myopathy, congenital myopathy, myasthenia gravis, motor neuron disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and cervical myelopathy.(4)In this study, we present an intriguing and previously undocumented case of DHS. Unlike commonly reported causes of DHS, such as neuromuscular disorders or structural abnormalities, our case diverges from these conventional etiologies. This unique presentation challenges existing paradigms and underscores the importance of further investigation into less conventional pathways leading to DHS. By thoroughly examining the patient’s medical history, clinical presentation, and diagnostic findings, we aim to contribute insights that broaden our understanding of the etiological spectrum of DHS.Case History:A 23-year-old male with a progressive cervical spine deformity and dropped head, ongoing for the past 15 months, presented to the neurosurgery outpatient clinic. The patient is experiencing chronic neck pain and upper limb paresthesia. He appears to have a slight build and exhibits a pronounced forward-bending head posture. Additionally, there is markedly restricted range of motion (ROM) in the cervical spine, with the chin nearly in contact with the sternum manubrium. He has no history of severe neck trauma or neck surgery, and the kyphosis is not passively correctible.The patient, hailing from a socioeconomically disadvantaged background, has a significant medical history of major depressive disorder and substance abuse, including addiction to heroin, opium, and amphetamines. After every episode of amphetamine use, the patient consistently maintained a fixed kyphotic neck position for extended periods, leading to a progressive alteration in his cervical alignment. Prior to this history of addiction, there was no malalignment in his neck.During physical examination, inspection and palpation of the cervical spine revealed a pronounced kyphoscoliosis deformity. Cranial nerve testing yielded normal results. Muscle strength assessment indicated a rating of 4/5 in the upper limbs and 5/5 in the lower limbs. Upper limb paresthesia was observed, with unspecified sensory level. Deep tendon reflexes (DTRs) in the upper limbs were within normal limits, while those in the lower limbs showed a slight exaggeration. Autonomic functions were normal, and there was no evidence of sphincter dysfunction. The patient had tried various traditional and herbal remedies, but none had alleviated his symptoms.As described above, due to the severe deformity of the neck, he was admitted to our department at Al-Zahra hospital in Isfahan city, Isfahan, Iran (figure 1).The cervical CT scan revealed a severe kyphoscoliosis deformity affecting C3, C4, and C5, accompanied by degenerative joint disease (DJD) changes in the anterior aspect of these vertebrae. No evidence of canal stenosis or fractures was observed. Subsequent MRI confirmed cervical kyphoscoliosis with unremarkable cervical cord features. Following comprehensive clinical and radiological assessment and considering the severity of the cervical spine deformity, a decision was made to proceed with a three-stage surgical intervention during a single anesthesia session.

  • Open Access

    Alemtuzumab‐induced petechiae and epistaxis in a patient with relapsing–remitting multiple sclerosis: A case report

    by Farhad Mahmoudi, Sayed Ali Emami, Farid Masaeli, Najmeh Rayatpisheh

    Key clinical message: Here, we present a case of relapsing–remitting multiple sclerosis that experienced petechiae and epistaxis following treatment with second dose of alemtuzumab. This study highlights such effects, emphasizing the need for vigilance as alemtuzumab usage increases. Timely recognition and management are vital for patient care.